Paul Perreault, CSL CEO

M&A sea­son starts ear­ly? CSL seals $11.7B ac­qui­si­tion of Vi­for Phar­ma

Aus­tralia’s CSL is plop­ping down $11.7 bil­lion to ac­quire Vi­for Phar­ma, the Swiss biotech best known for its iron prod­ucts and kid­ney drugs.

While the buy­out comes as lit­tle sur­prise — ru­mors have swirled since ear­ly De­cem­ber, and Vi­for ac­tu­al­ly con­firmed the deal talks to me­dia on Mon­day — the fi­nal price could raise some eye­brows.

At $179.25 per share, CSL’s of­fer comes in much high­er than the “more than $8.5 bil­lion” price tag cit­ed in re­ports.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters